Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis
Recovery setup
Healthcare · Biotechnology
Sell if holding. Momentum 4.1/10 is below the 5.0 floor at $63.21 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: XDEMVY; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.3).
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company with XDEMVY (lotilaner ophthalmic solution), the first and only FDA-approved treatment for Demodex blepharitis, generating over $646 million in net product sales since its August 2023 launch. Additional... Read more
Sell if holding. Momentum 4.1/10 is below the 5.0 floor at $63.21 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: XDEMVY; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.3). Chart setup: Death cross but MACD improving, RSI 49. Score 6.0/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 78d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Tarsus Pharmaceuticals, Inc.
Latest news
- Earnings call transcript: Tarsus Pharmaceuticals Q1 2026 beats EPS forecast, stock dips - Investing.com Australia — Investing.com Australia positive
- Earnings call transcript: Tarsus Pharmaceuticals Q1 2026 beats EPS forecast, stock dips - Investing.com Canada — Investing.com Canada positive
- Earnings call transcript: Tarsus Pharmaceuticals Q1 2026 beats EPS forecast, stock dips - Investing.com — Investing.com positive
- Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance Australia — Yahoo Finance Australia positive
- Tarsus (TARS) Q1 2026 Earnings Transcript - The Globe and Mail — The Globe and Mail positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductXDEMVY10-K Item 1A: 'We have one product, XDEMVY®, formerly known as TP-03, which obtained Food and Drug Administration ("FDA") approval for the treatment of Demodex blepharitis in the U.S. in July 2023.'
Material Events(8-K, last 90d)
- 2026-02-18Item 5.02LOWDavid E.I. Pyott appointed to Board of Directors effective February 18, 2026, expanding board from 7 to 8. Named Chair of Commercial Committee and member of Nominating and Compensation Committees. Routine board expansion; no arrangement with any other person cited.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Momentum 4.1/10 is below the 5.0 floor at $63.21 — engine's falling-knife protection flags exit rather than catching a breakdown. Specifics: Concentration risk — Product: XDEMVY; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.3). Chart setup: Death cross but MACD improving, RSI 49. Prior stop was $58.65. Score 6.0/10, moderate confidence.
Take-profit target: $81.97 (+30.0% upside). Prior stop was $58.65. Stop-loss: $58.65.
Concentration risk — Product: XDEMVY; V7 low-quality RISK_OFF penalty: -0.5 (Q=4.3); Consecutive earnings misses (2).
Tarsus Pharmaceuticals, Inc. trades at a P/E of N/A (forward 22.4). TrendMatrix value score: 7.7/10. Verdict: Sell.
15 analysts cover TARS with a consensus score of 4.4/5. Average price target: $94.
What does Tarsus Pharmaceuticals, Inc. do?Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company with XDEMVY (lotilaner ophthalmic solution), the...
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company with XDEMVY (lotilaner ophthalmic solution), the first and only FDA-approved treatment for Demodex blepharitis, generating over $646 million in net product sales since its August 2023 launch. Additional pipeline candidates include TP-04 (Phase 2, ocular rosacea) and TP-05 (Lyme disease prophylaxis).